113 related articles for article (PubMed ID: 26567125)
1. Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer.
Lee KW; Lee JH; Kim JW; Kim JW; Ahn S; Kim JH
J Cancer Res Clin Oncol; 2016 Mar; 142(3):687-97. PubMed ID: 26567125
[TBL] [Abstract][Full Text] [Related]
2. A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study.
Choi IS; Kim JH; Lee JH; Suh KJ; Lee JY; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
PLoS One; 2018; 13(10):e0205853. PubMed ID: 30346970
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Choi IS; Choi M; Lee JH; Kim JH; Suh KJ; Lee JY; Kang B; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
PLoS One; 2018; 13(6):e0198544. PubMed ID: 29879177
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns Among Patients with Metastatic and/or Unresectable Gastric Cancer in Brazil.
de Alencar Camara Vieira FM; de Souza Victorino APO; de Iracema Gomes Cubero D; Beato CAM; Minowa E; Julian GS; Novick D
J Gastrointest Cancer; 2019 Dec; 50(4):780-793. PubMed ID: 30078125
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.
Carter GC; Kaltenboeck A; Ivanova J; Liepa AM; San Roman A; Koh M; Rajan N; Cheng R; Birnbaum HG; Kim JS; Bang YJ
Cancer Res Treat; 2017 Jul; 49(3):578-587. PubMed ID: 27618820
[TBL] [Abstract][Full Text] [Related]
6. Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer.
McLean J; Rho YS; Kuruba G; Mamo A; Gilabert M; Kavan T; Panasci L; Melnychuk D; Batist G; Kavan P
Clin Colorectal Cancer; 2016 Jun; 15(2):135-40. PubMed ID: 26553578
[TBL] [Abstract][Full Text] [Related]
7. Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients?
Kim ST; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2012 Jun; 8(2):194-200. PubMed ID: 22524579
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of medical oncologists.
Wood LA; Fields AL
Br J Cancer; 2004 May; 90(10):1885-7. PubMed ID: 15138466
[TBL] [Abstract][Full Text] [Related]
9. Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: Evidence from the American College of Surgeons National Cancer Database.
Greenleaf EK; Hollenbeak CS; Wong J
Surgery; 2016 Apr; 159(4):1099-112. PubMed ID: 26704785
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients.
Park SR; Kook MC; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Lee JS; Park YI; Kim NK
Cancer Chemother Pharmacol; 2010 Feb; 65(3):579-87. PubMed ID: 19629485
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of young-age onset gastric cancer in Korea.
Lee J; Lee MA; Kim IH; Roh SY
BMC Gastroenterol; 2016 Sep; 16(1):110. PubMed ID: 27600152
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Brieau B; Auzolle C; Pozet A; Tougeron D; Bouché O; Soibinet P; Coriat R; Prieux C; Lecomte T; Goujon G; Marthey L; Rougier P; Bonnetain F; Ducreux M; Taieb J; Zaanan A
Dig Liver Dis; 2016 Apr; 48(4):441-5. PubMed ID: 26775096
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns in patients with advanced gastric cancer in Taiwan.
Cuyun Carter G; Kaltenboeck A; Ivanova J; Liepa AM; San Roman A; Koh M; Rajan N; Cheng R; Birnbaum H; Chen JS
Asia Pac J Clin Oncol; 2017 Jun; 13(3):185-194. PubMed ID: 27108762
[TBL] [Abstract][Full Text] [Related]
15. FOLFOX (oxaliplatin and 5 fluorouracil/leucovorin) in patients with untreated metastatic gastric adenocarcinoma Phase II study.
Mohammad HA; Magdy FM; Mahmoud OM
Indian J Cancer; 2011; 48(4):460-5. PubMed ID: 22293261
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
17. Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlier.
Recchia F; Candeloro G; Guerriero G; Piazze J; Desideri G; Necozione S; Rea S
Anticancer Drugs; 2010 Jun; 21(5):559-64. PubMed ID: 20308874
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
Goto A; Sukawa Y; Igarashi H; Onodera K; Aoki Y; Suzuki K; Yonezawa K; Yawata A; Kobayashi T; Kaneto H; Shimizu H; Wakasugi H; Matsunaga Y; Itoh M; Okuda H; Arimura Y; Shinomura Y
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1461-6. PubMed ID: 21945893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
